{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T22:25:31Z","timestamp":1788474331318,"version":"build-2803163510"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-11856-1","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T07:12:11Z","timestamp":1777101131000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["mRNA vaccines for viral diseases: mechanism, advances, and future perspective"],"prefix":"10.1007","volume":"53","author":[{"given":"Bhumika","family":"Chakraborty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taru","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"issue":"11","key":"11856_CR1","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","volume":"20","author":"N Chaudhary","year":"2021","unstructured":"Chaudhary N, Weissman D, Whitehead KA (2021) mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discov 20(11):817\u2013838. https:\/\/doi.org\/10.1038\/s41573-021-00283-5","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"11856_CR2","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3390\/vaccines13060601","volume":"13","author":"S Oloruntimehin","year":"2025","unstructured":"Oloruntimehin S, Akinyi F, Paul M, Ariyo O (2025) mRNA vaccine technology beyond COVID-19. Vaccines 13(6):601. https:\/\/doi.org\/10.3390\/vaccines13060601","journal-title":"Vaccines"},{"key":"11856_CR3","unstructured":"World Health Organization. Worldwide measles deaths climbed 50% from 2016 to 2019, claiming over 207,500 lives in 2019, WHO (2020) Nov 12. Available from: https:\/\/www.who.int\/news\/item\/12-11-2020-worldwide-measles-deaths-climb-50-from-2016-to-2019-claiming-over-207500-lives-in-2019"},{"key":"11856_CR4","unstructured":"World Health Organization WHO lists 10th COVID-19 vaccine for emergency use: Nuvaxovid. Geneva: WHO; 21 Dec 2021. Available from: https:\/\/www.who.int\/news\/item\/21-12-2021-who-lists-10th-covid-19-vaccine-for-emergency-use-nuvaxovid"},{"key":"11856_CR5","doi-asserted-by":"publisher","first-page":"1247041","DOI":"10.3389\/fmicb.2023.1247041","volume":"14","author":"RJ Shattock","year":"2023","unstructured":"Shattock RJ, Andrianaivoarimanana V, McKay PF, Randriantseheno LN, Murugaiah V, Samnuan K, Rogers P, Tregoning JS, Rajerison M, Moore KM, Laws TR, Williamson ED (2023) A self-amplifying RNA vaccine provides protection in a murine model of bubonic plague. Front Microbiol 14:1247041. https:\/\/doi.org\/10.3389\/fmicb.2023.1247041","journal-title":"Front Microbiol"},{"issue":"2","key":"11856_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","volume":"21","author":"AJ Pollard","year":"2021","unstructured":"Pollard AJ, Bijker EM (2021) A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol 21(2):83\u2013100. https:\/\/doi.org\/10.1038\/s41577-020-00479-7","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"11856_CR7","doi-asserted-by":"publisher","first-page":"5255","DOI":"10.1080\/21645515.2021.1977057","volume":"17","author":"V Kayser","year":"2021","unstructured":"Kayser V, Ramzan I (2021) Vaccines and vaccination: history and emerging issues. Hum Vaccin Immunother 17(12):5255\u20135268. https:\/\/doi.org\/10.1080\/21645515.2021.1977057","journal-title":"Hum Vaccin Immunother"},{"key":"11856_CR8","unstructured":"Ritchie H, Roser M et al (2024) Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization. Lancet. Available from: https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(24)00850-X\/fulltext"},{"issue":"34","key":"11856_CR9","doi-asserted-by":"publisher","first-page":"12283","DOI":"10.1073\/pnas.1400472111","volume":"111","author":"S Plotkin","year":"2014","unstructured":"Plotkin S (2014) History of vaccination. Proc Natl Acad Sci U S A 111(34):12283\u201312287. https:\/\/doi.org\/10.1073\/pnas.1400472111","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"11856_CR10","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.3390\/ijms24032700","volume":"24","author":"V Gote","year":"2023","unstructured":"Gote V, Bolla PK, Kommineni N, Butreddy A, Nukala PK, Palakurthi SS et al (2023) A comprehensive review of mRNA vaccines. Int J Mol Sci 24(3):2700. https:\/\/doi.org\/10.3390\/ijms24032700","journal-title":"Int J Mol Sci"},{"key":"11856_CR11","volume-title":"WHO global report on traditional and complementary medicine 2019","author":"World Health Organization","year":"2019","unstructured":"World Health Organization (2019) WHO global report on traditional and complementary medicine 2019. World Health Organization, Geneva. https:\/\/iris.who.int\/handle\/10665\/312342"},{"key":"11856_CR12","unstructured":"World Health Organization. Measles \u2013 background Q&A, WHO (2025) Available from: https:\/\/www.who.int\/docs\/default-source\/immunization\/measles\/measles--q-a.pdf"},{"issue":"5","key":"11856_CR13","doi-asserted-by":"publisher","first-page":"e84529","DOI":"10.7759\/cureus.84529","volume":"17","author":"S Saxena","year":"2025","unstructured":"Saxena S, Mandrah V, Tariq W, Das P, Sambhav K, Devi SH (2025) The future of mRNA vaccines: potential beyond COVID-19. Cureus 17(5):e84529. https:\/\/doi.org\/10.7759\/cureus.84529","journal-title":"Cureus"},{"issue":"1","key":"11856_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10238-023-01264-1","volume":"24","author":"A Boretti","year":"2024","unstructured":"Boretti A (2024) mRNA vaccine boosters and impaired immune system response in immune-compromised individuals: a narrative review. Clin Exp Med 24(1):23. https:\/\/doi.org\/10.1007\/s10238-023-01264-1","journal-title":"Clin Exp Med"},{"issue":"10","key":"11856_CR15","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.32604\/or.2024.043987","volume":"32","author":"S Chandra","year":"2024","unstructured":"Chandra S, Wilson JC, Good D, Wei MQ (2024) mRNA vaccines: a new era in vaccine development. Oncol Res 32(10):1543\u20131564. https:\/\/doi.org\/10.32604\/or.2024.043987","journal-title":"Oncol Res"},{"issue":"4","key":"11856_CR16","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW, Weissman D (2018) mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov 17(4):261\u2013279. https:\/\/doi.org\/10.1038\/nrd.2017.243. doi: [10.1038\/nrd.2017.243](","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"11856_CR17","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"U Sahin","year":"2014","unstructured":"Sahin U, Karik\u00f3 K, T\u00fcreci \u00d6 (2014) mRNA-based therapeutics\u2014developing a new class of drugs. Nat Rev Drug Discov 13(10):759\u2013780. https:\/\/doi.org\/10.1038\/nrd4278","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"11856_CR18","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","volume":"27","author":"PS Kowalski","year":"2019","unstructured":"Kowalski PS, Rudra A, Miao L, Anderson DG (2019) Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Mol Ther 27(4):710\u2013728. https:\/\/doi.org\/10.1016\/j.ymthe.2019.02.012","journal-title":"Mol Ther"},{"issue":"27","key":"11856_CR19","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S et al (2020) Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 383(27):2603\u20132615. https:\/\/doi.org\/10.1056\/NEJMoa2034577","journal-title":"N Engl J Med"},{"issue":"20","key":"11856_CR20","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","volume":"383","author":"LA Jackson","year":"2020","unstructured":"Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN et al (2020) An mRNA vaccine against SARS-CoV-2\u2014preliminary report. N Engl J Med 383(20):1920\u20131931. https:\/\/doi.org\/10.1056\/NEJMoa2022483","journal-title":"N Engl J Med"},{"key":"11856_CR21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.coi.2020.01.008","volume":"65","author":"N Pardi","year":"2020","unstructured":"Pardi N, Hogan MJ, Weissman D (2020) Recent advances in mRNA vaccine technology. Curr Opin Immunol 65:14\u201320. https:\/\/doi.org\/10.1016\/j.coi.2020.01.008","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"11856_CR22","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","volume":"7","author":"E Fang","year":"2022","unstructured":"Fang E, Liu X, Li M, Zhang Z, Song L, Zhu B et al (2022) Advances in COVID-19 mRNA vaccine development. Signal Transduct Target Ther 7(1):94. https:\/\/doi.org\/10.1038\/s41392-022-00950-y","journal-title":"Signal Transduct Target Ther"},{"key":"11856_CR23","unstructured":"Henly H, White Papers (2021) May mRNA vaccines: is the future now? Research and. Available from: https:\/\/www.rgare.com\/knowledge-center\/article\/mrna-vaccines-is-the-future-now"},{"key":"11856_CR24","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1038\/s41564-024-01770-2","volume":"9","author":"S Pecetta","year":"2024","unstructured":"Pecetta S, Rappuoli R (2024) The evolving landscape of live attenuated COVID-19 vaccines. Nat Microbiol 9:1911\u20131913. https:\/\/doi.org\/10.1038\/s41564-024-01770-2","journal-title":"Nat Microbiol"},{"issue":"4","key":"11856_CR25","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s12272-022-01381-7","volume":"45","author":"S Kwon","year":"2022","unstructured":"Kwon S, Kwon M, Im S, Lee K, Lee H (2022) mRNA vaccines: the most recent clinical applications of synthetic mRNA. Arch Pharm Res 45(4):245\u2013262. https:\/\/doi.org\/10.1007\/s12272-022-01381-7","journal-title":"Arch Pharm Res"},{"key":"11856_CR26","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.coi.2018.04.024","volume":"53","author":"JM Richner","year":"2018","unstructured":"Richner JM, Diamond MS (2018) Zika virus vaccines: immune response, current status, and future challenges. Curr Opin Immunol 53:130\u2013136. https:\/\/doi.org\/10.1016\/j.coi.2018.04.024","journal-title":"Curr Opin Immunol"},{"key":"11856_CR27","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.3389\/fimmu.2020.01181","volume":"11","author":"RB Kennedy","year":"2020","unstructured":"Kennedy RB, Ovsyannikova IG, Palese P, Poland GA (2020) Current challenges in vaccinology. Front Immunol 11:1181. https:\/\/doi.org\/10.3389\/fimmu.2020.01181","journal-title":"Front Immunol"},{"issue":"5","key":"11856_CR28","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/s1369-5274(00)00119-3","volume":"3","author":"R Rappuoli","year":"2000","unstructured":"Rappuoli R (2000) Reverse vaccinology. Curr Opin Microbiol 3(5):445\u2013450. https:\/\/doi.org\/10.1016\/s1369-5274(00)00119-3","journal-title":"Curr Opin Microbiol"},{"issue":"15","key":"11856_CR29","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/s0264-410x(99)00434-x","volume":"18","author":"MR Hilleman","year":"2000","unstructured":"Hilleman MR (2000) Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. Vaccine 18(15):1436\u20131447. https:\/\/doi.org\/10.1016\/s0264-410x(99)00434-x","journal-title":"Vaccine"},{"issue":"3","key":"11856_CR30","doi-asserted-by":"publisher","first-page":"e10060","DOI":"10.1002\/amp2.10060","volume":"2","author":"Z Kis","year":"2020","unstructured":"Kis Z, Kontoravdi C, Dey AK, Shattock R, Shah N (2020) Rapid development and deployment of high-volume vaccines for pandemic response. J Adv Manuf Process 2(3):e10060. https:\/\/doi.org\/10.1002\/amp2.10060","journal-title":"J Adv Manuf Process"},{"issue":"11","key":"11856_CR31","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","volume":"55","author":"R Verbeke","year":"2022","unstructured":"Verbeke R, Hogan MJ, Lor\u00e9 K, Pardi N (2022) Innate immune mechanisms of mRNA vaccines. Immunity 55(11):1993\u20132005. https:\/\/doi.org\/10.1016\/j.immuni.2022.10.014","journal-title":"Immunity"},{"issue":"7","key":"11856_CR32","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41587-019-0164-5","volume":"37","author":"PJ Sample","year":"2019","unstructured":"Sample PJ, Wang B, Reid DW, Presnyak V, McFadyen IJ, Morris DR et al (2019) Human 5\u2032 UTR design and variant effect prediction from a massively parallel translation assay. Nat Biotechnol 37(7):803\u2013809. https:\/\/doi.org\/10.1038\/s41587-019-0164-5","journal-title":"Nat Biotechnol"},{"issue":"4","key":"11856_CR33","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.ymthe.2018.12.011","volume":"27","author":"AG von Orlandini","year":"2019","unstructured":"von Orlandini AG, Poleganov MA, Rechner C, Plaschke A, Kranz LM, Fesser S et al (2019) Improving mRNA-based therapeutic gene delivery by expression-augmenting 3\u2032 UTRs. Mol Ther 27(4):824\u2013836. https:\/\/doi.org\/10.1016\/j.ymthe.2018.12.011","journal-title":"Mol Ther"},{"issue":"2","key":"11856_CR34","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/pharmaceutics12020102","volume":"12","author":"A Wadhwa","year":"2020","unstructured":"Wadhwa A, Aljabbari A, Lokras A, Foged C, Thakur A (2020) Opportunities and challenges in the delivery of mRNA-based vaccines. Pharmaceutics 12(2):102. https:\/\/doi.org\/10.3390\/pharmaceutics12020102","journal-title":"Pharmaceutics"},{"issue":"10","key":"11856_CR35","doi-asserted-by":"publisher","first-page":"5281","DOI":"10.1007\/s12274-018-2146-1","volume":"11","author":"Q Xiong","year":"2018","unstructured":"Xiong Q, Lee GY, Ding J, Li W, Shi J (2018) Biomedical applications of mRNA nanomedicine. Nano Res 11(10):5281\u20135309. https:\/\/doi.org\/10.1007\/s12274-018-2146-1","journal-title":"Nano Res"},{"issue":"3","key":"11856_CR36","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.molmed.2019.10.002","volume":"26","author":"S Linares-Fern\u00e1ndez","year":"2020","unstructured":"Linares-Fern\u00e1ndez S, Lacroix C, Exposito JY, Verrier B (2020) Tailoring mRNA vaccine to balance innate\/adaptive immune response. Trends Mol Med 26(3):311\u2013323. https:\/\/doi.org\/10.1016\/j.molmed.2019.10.002","journal-title":"Trends Mol Med"},{"key":"11856_CR37","doi-asserted-by":"publisher","first-page":"107534","DOI":"10.1016\/j.biotechadv.2020.107534","volume":"40","author":"Y Weng","year":"2020","unstructured":"Weng Y, Li C, Yang T, Hu B, Zhang M, Guo S et al (2020) The challenge and prospect of the mRNA therapeutics landscape. Biotechnol Adv 40:107534. https:\/\/doi.org\/10.1016\/j.biotechadv.2020.107534","journal-title":"Biotechnol Adv"},{"issue":"11","key":"11856_CR38","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S0968-0004(00)89102-1","volume":"20","author":"CY Chen","year":"1995","unstructured":"Chen CY, Shyu AB (1995) AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem Sci 20(11):465\u2013470. https:\/\/doi.org\/10.1016\/S0968-0004(00)89102-1","journal-title":"Trends Biochem Sci"},{"issue":"16","key":"11856_CR39","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1016\/j.vaccine.2021.03.038","volume":"39","author":"SS Rosa","year":"2021","unstructured":"Rosa SS, Prazeres DMF, Azevedo AM, Marques MPC (2021) mRNA vaccines manufacturing: challenges and bottlenecks. Vaccine 39(16):2190\u20132200. https:\/\/doi.org\/10.1016\/j.vaccine.2021.03.038","journal-title":"Vaccine"},{"key":"11856_CR40","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41378-023-00538-8","volume":"9","author":"H Wei","year":"2023","unstructured":"Wei H, Rong Z, Liu L, Sang Y, Yang J, Wang S (2023) Streamlined and on-demand preparation of mRNA products on a universal integrated platform. Microsyst Nanoeng 9:97. https:\/\/doi.org\/10.1038\/s41378-023-00538-8","journal-title":"Microsyst Nanoeng"},{"issue":"6","key":"11856_CR41","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","volume":"26","author":"S Sabnis","year":"2018","unstructured":"Sabnis S, Kumarasinghe ES, Salerno T, Mihai C, Ketova T, Senn JJ et al (2018) A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates. Mol Ther 26(6):1509\u20131519. https:\/\/doi.org\/10.1016\/j.ymthe.2018.03.010","journal-title":"Mol Ther"},{"issue":"1","key":"11856_CR42","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41467-020-14527-2","volume":"11","author":"S Patel","year":"2020","unstructured":"Patel S, Ashwanikumar N, Robinson E, Xia Y, Mihai C, Griffith JP 3rd et al (2020) Naturally occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA. Nat Commun 11(1):983. https:\/\/doi.org\/10.1038\/s41467-020-14527-2","journal-title":"Nat Commun"},{"issue":"5","key":"11856_CR43","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1073\/pnas.0910603106","volume":"107","author":"KT Love","year":"2010","unstructured":"Love KT, Mahon KP, Levins CG, Whitehead KA, Querbes W, Dorkin JR et al (2010) Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci U S A 107(5):1864\u20131869. https:\/\/doi.org\/10.1073\/pnas.0910603106","journal-title":"Proc Natl Acad Sci U S A"},{"key":"11856_CR44","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.1038\/ncomms5277","volume":"5","author":"KA Whitehead","year":"2014","unstructured":"Whitehead KA, Dorkin JR, Vegas AJ, Chang PH, Veiseh O, Matthews J et al (2014) Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity. Nat Commun 5:4277. https:\/\/doi.org\/10.1038\/ncomms5277","journal-title":"Nat Commun"},{"key":"11856_CR45","doi-asserted-by":"publisher","unstructured":"Wang C, Zhang Y, Dong Y (2021). Lipid Nanoparticle-mRNA Formulations for Therapeutic Applications. Acc chem res 54(23), 4283\u20134293. https:\/\/doi.org\/10.1021\/acs.accounts.1c00550","DOI":"10.1021\/acs.accounts.1c00550"},{"issue":"1","key":"11856_CR46","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1038\/s41467-020-16248-y","volume":"11","author":"L Miao","year":"2020","unstructured":"Miao L, Lin J, Huang Y, Li L, Delcassian D, Ge Y et al (2020) Synergistic lipid compositions for albumin receptor-mediated delivery of mRNA to the liver. Nat Commun 11(1):2424. https:\/\/doi.org\/10.1038\/s41467-020-16248-y","journal-title":"Nat Commun"},{"issue":"10","key":"11856_CR47","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1038\/s41587-019-0247-3","volume":"37","author":"L Miao","year":"2019","unstructured":"Miao L, Li L, Huang Y, Delcassian D, Chahal J, Han J et al (2019) Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat Biotechnol 37(10):1174\u20131185. https:\/\/doi.org\/10.1038\/s41587-019-0247-3","journal-title":"Nat Biotechnol"},{"issue":"11","key":"11856_CR48","doi-asserted-by":"publisher","first-page":"7300","DOI":"10.1021\/acs.nanolett.5b02497","volume":"15","author":"KJ Kauffman","year":"2015","unstructured":"Kauffman KJ, Dorkin JR, Yang JH, Heartlein MW, DeRosa F, Mir FF et al (2015) Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs. Nano Lett 15(11):7300\u20137306. https:\/\/doi.org\/10.1021\/acs.nanolett.5b02497","journal-title":"Nano Lett"},{"issue":"6","key":"11856_CR49","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1021\/acs.nanolett.8b01101","volume":"18","author":"RL Ball","year":"2018","unstructured":"Ball RL, Hajj KA, Vizelman J, Bajaj P, Whitehead KA (2018) Lipid nanoparticle formulations for enhanced co-delivery of siRNA and mRNA. Nano Lett 18(6):3814\u20133822. https:\/\/doi.org\/10.1021\/acs.nanolett.8b01101","journal-title":"Nano Lett"},{"key":"11856_CR50","doi-asserted-by":"publisher","first-page":"15810","DOI":"10.1038\/srep15810","volume":"5","author":"A Matsui","year":"2015","unstructured":"Matsui A, Uchida S, Ishii T, Itaka K, Kataoka K (2015) Messenger RNA-based therapeutics for the treatment of apoptosis-associated diseases. Sci Rep 5:15810. https:\/\/doi.org\/10.1038\/srep15810","journal-title":"Sci Rep"},{"issue":"4","key":"11856_CR51","doi-asserted-by":"publisher","first-page":"E448","DOI":"10.1073\/pnas.1614193114","volume":"114","author":"CJ McKinlay","year":"2017","unstructured":"McKinlay CJ, Vargas JR, Blake TR, Hardy JW, Kanada M, Contag CH et al (2017) Charge-altering releasable transporters for the delivery and release of mRNA in living animals. Proc Natl Acad Sci U S A 114(4):E448\u2013E456. https:\/\/doi.org\/10.1073\/pnas.1614193114","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"11856_CR52","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1038\/mt.2014.133","volume":"22","author":"LA Brito","year":"2014","unstructured":"Brito LA, Chan M, Shaw CA, Hekele A, Carsillo T, Schaefer M et al (2014) A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol Ther 22(12):2118\u20132129. https:\/\/doi.org\/10.1038\/mt.2014.133","journal-title":"Mol Ther"},{"issue":"7","key":"11856_CR53","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.3109\/10717544.2015.1038856","volume":"23","author":"M Zhao","year":"2016","unstructured":"Zhao M, Li M, Zhang Z, Gong T, Sun X (2016) Induction of HIV-1 gag-specific immune responses by cationic micelles mediated delivery of gag mRNA. Drug Deliv 23(7):2596\u20132607. https:\/\/doi.org\/10.3109\/10717544.2015.1038856","journal-title":"Drug Deliv"},{"key":"11856_CR54","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.addr.2020.12.014","volume":"170","author":"J Kim","year":"2021","unstructured":"Kim J, Eygeris Y, Gupta M, Sahay G (2021) Self-assembled mRNA vaccines. Adv Drug Deliv Rev 170:83\u2013112. https:\/\/doi.org\/10.1016\/j.addr.2020.12.014","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"11856_CR55","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41565-019-0600-1","volume":"15","author":"X Hou","year":"2020","unstructured":"Hou X, Zhang X, Zhao W, Zeng C, Deng B, McComb DW et al (2020) Vitamin lipid nanoparticles enable adoptive macrophage transfer for the treatment of multidrug-resistant bacterial sepsis. Nat Nanotechnol 15(1):41\u201346. https:\/\/doi.org\/10.1038\/s41565-019-0600-1","journal-title":"Nat Nanotechnol"},{"issue":"Suppl 3","key":"11856_CR56","doi-asserted-by":"publisher","first-page":"C8","DOI":"10.1016\/j.vaccine.2008.04.011","volume":"26","author":"MF Boni","year":"2008","unstructured":"Boni MF (2008) Vaccination and antigenic drift in influenza. Vaccine 26(Suppl 3):C8\u2013C14. https:\/\/doi.org\/10.1016\/j.vaccine.2008.04.011","journal-title":"Vaccine"},{"issue":"7","key":"11856_CR57","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","volume":"25","author":"PR Cullis","year":"2017","unstructured":"Cullis PR, Hope MJ (2017) Lipid nanoparticle systems for enabling gene therapies. Mol Ther 25(7):1467\u20131475. https:\/\/doi.org\/10.1016\/j.ymthe.2017.03.013","journal-title":"Mol Ther"},{"key":"11856_CR58","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.omtm.2020.07.013","volume":"18","author":"M Zhang","year":"2020","unstructured":"Zhang M, Sun J, Li M, Jin X (2020) Modified mRNA-LNP vaccines confer protection against experimental DENV-2 infection in mice. Mol Ther Methods Clin Dev 18:702\u2013712. https:\/\/doi.org\/10.1016\/j.omtm.2020.07.013","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"10","key":"11856_CR59","doi-asserted-by":"publisher","first-page":"E1941","DOI":"10.1073\/pnas.1619653114","volume":"114","author":"S Ramaswamy","year":"2017","unstructured":"Ramaswamy S, Tonnu N, Tachikawa K, Limphong P, Vega JB, Karmali PP et al (2017) Systemic delivery of factor IX messenger RNA for protein replacement therapy. Proc Natl Acad Sci U S A 114(10):E1941\u2013E1950. https:\/\/doi.org\/10.1073\/pnas.1619653114","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"11856_CR60","doi-asserted-by":"publisher","first-page":"4493","DOI":"10.1038\/s41467-018-06936-1","volume":"9","author":"N Veiga","year":"2018","unstructured":"Veiga N, Goldsmith M, Granot Y, Rosenblum D, Dammes N, Kedmi R et al (2018) Cell-specific delivery of modified mRNA expressing therapeutic proteins to leukocytes. Nat Commun 9(1):4493. https:\/\/doi.org\/10.1038\/s41467-018-06936-1","journal-title":"Nat Commun"},{"issue":"10","key":"11856_CR61","doi-asserted-by":"publisher","first-page":"6449","DOI":"10.1021\/acs.nFanolett.8b02917","volume":"18","author":"JC Kaczmarek","year":"2018","unstructured":"Kaczmarek JC, Kauffman KJ, Fenton OS, Sadtler K, Patel AK, Heartlein MW et al (2018) Optimization of a degradable polymer-lipid nanoparticle for potent systemic delivery of mRNA to the lung endothelium and immune cells. Nano Lett 18(10):6449\u20136454. https:\/\/doi.org\/10.1021\/acs.nFanolett.8b02917","journal-title":"Nano Lett"},{"issue":"7","key":"11856_CR62","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.addr.2003.10.041","volume":"56","author":"W Li","year":"2004","unstructured":"Li W, Nicol F, Szoka FC Jr. (2004) GALA: a designed synthetic pH-responsive amphipathic peptide with applications in drug and gene delivery. Adv Drug Deliv Rev 56(7):967\u2013985. https:\/\/doi.org\/10.1016\/j.addr.2003.10.041","journal-title":"Adv Drug Deliv Rev"},{"issue":"7868","key":"11856_CR63","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41586-021-03653-6","volume":"595","author":"U Sahin","year":"2021","unstructured":"Sahin U, Muik A, Vogler I, Derhovanessian E, Kranz LM, Vormehr M et al (2021) BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature 595(7868):572\u2013577. https:\/\/doi.org\/10.1038\/s41586-021-03653-6","journal-title":"Nature"},{"issue":"9","key":"11856_CR64","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41434-019-0095-2","volume":"26","author":"AK Blakney","year":"2019","unstructured":"Blakney AK, McKay PF, Yus BI, Aldon Y, Shattock RJ (2019) Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA. Gene Ther 26(9):363\u2013372. https:\/\/doi.org\/10.1038\/s41434-019-0095-2","journal-title":"Gene Ther"},{"issue":"7644","key":"11856_CR65","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nature21428","volume":"543","author":"N Pardi","year":"2017","unstructured":"Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR et al (2017) Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 543(7644):248\u2013251. https:\/\/doi.org\/10.1038\/nature21428","journal-title":"Nature"},{"key":"11856_CR66","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.omtn.2019.03.003","volume":"15","author":"N Pardi","year":"2019","unstructured":"Pardi N, LaBranche CC, Ferrari G, Cain DW, Tomb\u00e1cz I, Parks RJ et al (2019) Characterization of HIV-1 nucleoside-modified mRNA vaccines in rabbits and rhesus macaques. Mol Ther Nucleic Acids 15:36\u201347. https:\/\/doi.org\/10.1016\/j.omtn.2019.03.003","journal-title":"Mol Ther Nucleic Acids"},{"issue":"2","key":"11856_CR67","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3390\/nano10020364","volume":"10","author":"I Gomez-Aguado","year":"2020","unstructured":"Gomez-Aguado I, Rodr\u00edguez-Castej\u00f3n J, Vicente-Pascual M, Rodr\u00edguez-Gasc\u00f3n A, Solin\u00eds M\u00c1 (2020) Del Pozo-Rodr\u00edguez A. Nanomedicines to deliver mRNA: state of the art and future perspectives. Nanomaterials 10(2):364. https:\/\/doi.org\/10.3390\/nano10020364","journal-title":"Nanomaterials"},{"key":"11856_CR68","doi-asserted-by":"publisher","unstructured":"Mbatha LS, Akinyelu J, Maiyo F, Kudanga T (2023) Future prospects in mRNA vaccine development. Biomed Mater 18(5). https:\/\/doi.org\/10.1088\/1748-605X\/aceceb","DOI":"10.1088\/1748-605X\/aceceb"},{"issue":"1","key":"11856_CR69","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41577-020-00470-2","volume":"21","author":"R Alon","year":"2021","unstructured":"Alon R, Sportiello M, Kozlovski S, Kumar A, Reilly EC, Zarbock A et al (2021) Leukocyte trafficking to the lungs and beyond: lessons from influenza for COVID-19. Nat Rev Immunol 21(1):49\u201364. https:\/\/doi.org\/10.1038\/s41577-020-00470-2","journal-title":"Nat Rev Immunol"},{"issue":"7798","key":"11856_CR70","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","volume":"579","author":"F Wu","year":"2020","unstructured":"Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG et al (2020) A new coronavirus associated with human respiratory disease in China. Nature 579(7798):265\u2013269. https:\/\/doi.org\/10.1038\/s41586-020-2008-3","journal-title":"Nature"},{"issue":"15","key":"11856_CR71","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","volume":"384","author":"N Dagan","year":"2021","unstructured":"Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA et al (2021) BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 384(15):1412\u20131423. https:\/\/doi.org\/10.1056\/NEJMoa2101765","journal-title":"N Engl J Med"},{"issue":"5","key":"11856_CR72","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/S1473-3099(22)00827-1","volume":"23","author":"A Wilder-Smith","year":"2023","unstructured":"Wilder-Smith A, Durbin A (2023) Promising efforts to develop an mRNA vaccine against Zika. Lancet Infect Dis 23(5):520\u2013522. https:\/\/doi.org\/10.1016\/S1473-3099(22)00827-1","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"11856_CR73","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.3390\/vaccines9121464","volume":"9","author":"LG Medina-Mag\u00fces","year":"2021","unstructured":"Medina-Mag\u00fces LG, Gergen J, Jasny E, Petsch B, Lopera-Madrid J, Medina-Mag\u00fces ES et al (2021) mRNA vaccine protects against Zika virus. Vaccines 9(12):1464. https:\/\/doi.org\/10.3390\/vaccines9121464","journal-title":"Vaccines"},{"issue":"10127","key":"11856_CR74","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","volume":"391","author":"AD Luliano","year":"2018","unstructured":"Luliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S et al (2018) Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet 391(10127):1285\u20131300. https:\/\/doi.org\/10.1016\/S0140-6736(17)33293-2","journal-title":"Lancet"},{"issue":"8","key":"11856_CR75","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1038\/emi.2013.54","volume":"2","author":"A Hekele","year":"2013","unstructured":"Hekele A, Bertholet S, Archer J, Gibson DG, Palladino G, Brito LA et al (2013) Rapidly produced SAM\u00ae vaccine against H7N9 influenza is immunogenic in mice. Emerg Microbes Infect 2(8):e52. https:\/\/doi.org\/10.1038\/emi.2013.54","journal-title":"Emerg Microbes Infect"},{"issue":"47","key":"11856_CR76","doi-asserted-by":"publisher","first-page":"12578","DOI":"10.1073\/pnas.1712377114","volume":"114","author":"SJ Zost","year":"2017","unstructured":"Zost SJ, Parkhouse K, Gumina ME, Kim K, Diaz Perez S, Wilson PC et al (2017) Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc Natl Acad Sci U S A 114(47):12578\u201312583. https:\/\/doi.org\/10.1073\/pnas.1712377114","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"11856_CR77","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/ni.3158","volume":"16","author":"DR Burton","year":"2015","unstructured":"Burton DR, Mascola JR (2015) Antibody responses to envelope glycoproteins in HIV-1 infection. Nat Immunol 16(6):571\u2013576. https:\/\/doi.org\/10.1038\/ni.3158","journal-title":"Nat Immunol"},{"key":"11856_CR78","doi-asserted-by":"crossref","unstructured":"Hess KL, Medintz IL, Jewell CM (2019) Designing inorganic nanomaterials for vaccines and immunotherapies. Nano Today. 27:73\u201398. https:\/\/doi.org\/10.1016\/j.nantod.2019.04.005. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1748013219300271","DOI":"10.1016\/j.nantod.2019.04.005"},{"key":"11856_CR79","doi-asserted-by":"crossref","unstructured":"Burton DR, Hangartner L (2016) Broadly neutralizing antibodies to HIV and their role in vaccine design. Annu Rev Immunol. 34:635\u2013659. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6034635\/","DOI":"10.1146\/annurev-immunol-041015-055515"},{"issue":"11","key":"11856_CR80","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","volume":"384","author":"L Corey","year":"2021","unstructured":"Corey L, Gilbert PB, Juraska M, Montefiori DC, Morris L, Karuna ST et al (2021) Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N Engl J Med 384(11):1003\u20131014. https:\/\/doi.org\/10.1056\/NEJMoa2031738","journal-title":"N Engl J Med"},{"issue":"4","key":"11856_CR81","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW, Weissman D (2018) mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov 17(4):261\u2013279. https:\/\/doi.org\/10.1038\/nrd.2017.243","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"11856_CR82","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou X, Zaks T, Langer R, Dong Y (2021) Lipid nanoparticles for mRNA delivery. Nat Rev Mater 6(12):1078\u20131094. https:\/\/doi.org\/10.1038\/s41578-021-00358-0","journal-title":"Nat Rev Mater"},{"key":"11856_CR83","doi-asserted-by":"publisher","first-page":"2500126","DOI":"10.1002\/anbr.202500126","volume":"5","author":"N Mendoza-Ram\u00edrez","year":"2025","unstructured":"Mendoza-Ram\u00edrez N, Juvenal G-C, Julio N-T, Gabriela C-B, Leticia (2025) Adv NanoBiomed Res 5:2500126. https:\/\/doi.org\/10.1002\/anbr.202500126","journal-title":"Adv NanoBiomed Res"},{"issue":"6","key":"11856_CR84","doi-asserted-by":"publisher","first-page":"4543","DOI":"10.1021\/acs.nanolett.0c01386","volume":"20","author":"Y Eygeris","year":"2020","unstructured":"Eygeris Y, Patel S, Jozic A, Sahay G (2020) Deconvoluting Lipid Nanoparticle Structure for Messenger RNA Delivery. Nano Lett 20(6):4543\u20134549. https:\/\/doi.org\/10.1021\/acs.nanolett.0c01386","journal-title":"Nano Lett"},{"issue":"3","key":"11856_CR85","doi-asserted-by":"publisher","first-page":"260","DOI":"10.22088\/IJMCM.BUMS.11.3.260","volume":"11","author":"V Koppu","year":"2022","unstructured":"Koppu V, Poloju D, Puvvala B, Madineni K, Balaji S, Sheela CMP et al (2022) Current perspectives and future prospects of mRNA vaccines against viral diseases: a brief review. Int J Mol Cell Med 11(3):260\u2013272. https:\/\/doi.org\/10.22088\/IJMCM.BUMS.11.3.260","journal-title":"Int J Mol Cell Med"},{"key":"11856_CR86","doi-asserted-by":"publisher","unstructured":"Chen B, Yang Y, Wang X, Yang W, Lu Y, Wang D, Zhuo E, Tang Y, Su J, Tang G, Shao S, Gu K (2024) mRNA vaccine development and applications: A special focus on tumors (Review). Int J Oncol. 65(2):81. https:\/\/doi.org\/10.3892\/ijo.2024.5669. Available from: https:\/\/doi.org\/10.3892\/ijo.2024.5669","DOI":"10.3892\/ijo.2024.5669"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11856-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11856-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11856-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:04:51Z","timestamp":1779357891000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11856-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11856"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11856-1","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"24 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"664"}}